000282299 001__ 282299
000282299 005__ 20251117100054.0
000282299 0247_ $$2doi$$a10.1212/WNL.0000000000214320
000282299 0247_ $$2pmid$$apmid:41232062
000282299 0247_ $$2pmc$$apmc:PMC12615013
000282299 0247_ $$2ISSN$$a0028-3878
000282299 0247_ $$2ISSN$$a1526-632X
000282299 037__ $$aDZNE-2025-01269
000282299 041__ $$aEnglish
000282299 082__ $$a610
000282299 1001_ $$avan Voorst, Romy J$$b0
000282299 245__ $$aConsensus-Based Expert Recommendations for Diagnosis and Clinical Management of Vanishing White Matter.
000282299 260__ $$aPhiladelphia, Pa.$$bWolters Kluwer$$c2025
000282299 3367_ $$2DRIVER$$aarticle
000282299 3367_ $$2DataCite$$aOutput Types/Journal article
000282299 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1763369831_17166$$xReview Article
000282299 3367_ $$2BibTeX$$aARTICLE
000282299 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282299 3367_ $$00$$2EndNote$$aJournal Article
000282299 520__ $$aVanishing white matter (VWM) is a rare disorder, characterized by degeneration of CNS white matter, clinically often exacerbated by stressors such as fever and minor head trauma. VWM is caused by biallelic pathogenic variants in the EIF2B1-5 genes, causing reduced activity of eukaryotic initiation of translation factor 2B, resulting in dysregulation of the integrated stress response (ISR). New scientific insights and increased clinical trials in experimental therapies highlight the need for clinical guidelines to improve and standardize care for patients with VWM worldwide. Standardized care is important for therapy development, as it lessens clinical variability of trial participants at study entry, enabling more sensitive evaluation of treatment outcomes. The aim of this study was to develop expert consensus-based recommendations for diagnosis and management of VWM. A real-time Delphi process with a multidisciplinary expert panel was conducted to formulate consensus-based recommendations. A literature review was performed to determine the strength of available evidence supporting each recommendation. The consensus yielded 43 recommendations on diagnosis, including genetic and MRI criteria, and on clinical management concerning disease progression, acute and long-term care, and preventive strategies. All known pathogenic and likely pathogenic EIF2B1-5 variants were identified from the literature and Amsterdam Leukodystrophy Center laboratory. An overview of these EIF2B1-5 variants was composed to facilitate diagnosis. Clinically used drugs may activate the ISR, posing a risk in VWM, or have no effect on or suppress the ISR, being probably safe in VWM. A second literature search explored the effects of clinically frequently used drugs on the ISR. Drugs were categorized into those likely to activate the ISR, suppress it, and have no likely effects on the ISR. Final judgment was achieved in a consensus meeting of experts. A patient management card was developed with input from clinical experts and patient advocates to provide information on these consensus-based recommendations in lay language and bridge the gap between scientific evidence and expert opinion on one side and the practical needs of clinicians and families on the other side. This study contributes to improving and standardizing VWM care based on scientific and expert insights, while highlighting key areas for future research.
000282299 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282299 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282299 650_7 $$2NLM Chemicals$$aEukaryotic Initiation Factor-2B
000282299 650_2 $$2MeSH$$aHumans
000282299 650_2 $$2MeSH$$aLeukoencephalopathies: therapy
000282299 650_2 $$2MeSH$$aLeukoencephalopathies: diagnosis
000282299 650_2 $$2MeSH$$aLeukoencephalopathies: genetics
000282299 650_2 $$2MeSH$$aConsensus
000282299 650_2 $$2MeSH$$aDisease Management
000282299 650_2 $$2MeSH$$aDelphi Technique
000282299 650_2 $$2MeSH$$aEukaryotic Initiation Factor-2B: genetics
000282299 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000282299 650_2 $$2MeSH$$aWhite Matter: diagnostic imaging
000282299 7001_ $$00000-0003-1601-7379$$aSchoenmakers, Daphne H$$b1
000282299 7001_ $$00000-0001-8775-147X$$aBonkowsky, Joshua L$$b2
000282299 7001_ $$00000-0002-6290-6751$$aVanderver, Adeline$$b3
000282299 7001_ $$0P:(DE-2719)9000936$$aKrägeloh-Mann, Ingeborg$$b4
000282299 7001_ $$00000-0002-9634-2966$$aBernard, Geneviève$$b5
000282299 7001_ $$00000-0001-9276-4590$$aBertini, Enrico$$b6
000282299 7001_ $$00000-0003-4116-6990$$aFatemi, Ali$$b7
000282299 7001_ $$00000-0002-7416-7108$$aSgobbi, Paulo V$$b8
000282299 7001_ $$00000-0003-1721-0728$$aWolf, Nicole I$$b9
000282299 7001_ $$00000-0002-2706-7163$$aGroeschel, Samuel$$b10
000282299 7001_ $$00000-0001-9371-7454$$aTonduti, Davide$$b11
000282299 7001_ $$00000-0002-5856-068X$$aSevin, Caroline$$b12
000282299 7001_ $$00000-0002-2909-1722$$aOrthmann-Murphy, Jennifer L$$b13
000282299 7001_ $$0P:(DE-2719)2810795$$aSchöls, Ludger$$b14
000282299 7001_ $$00000-0001-9167-1878$$aSalsano, Ettore$$b15
000282299 7001_ $$00000-0003-1394-3561$$aBrais, Bernard$$b16
000282299 7001_ $$aJaffe, Nicole$$b17
000282299 7001_ $$aTer Horst, Kasper W$$b18
000282299 7001_ $$aHannema, Sabine E$$b19
000282299 7001_ $$aHayes, Katherine G$$b20
000282299 7001_ $$aMeyburg, Jochen$$b21
000282299 7001_ $$avan Heerde, Marc$$b22
000282299 7001_ $$00009-0005-3682-8293$$aSbrocchi, Anne Marie$$b23
000282299 7001_ $$00000-0002-6077-8725$$avan Spaendonk, Rosalina$$b24
000282299 7001_ $$aThiffault, Isabelle$$b25
000282299 7001_ $$aHofsteenge, Geesje H$$b26
000282299 7001_ $$aSudmeier-Broek, Carolina$$b27
000282299 7001_ $$aTimmer, Corrie$$b28
000282299 7001_ $$aSkwirut, Donna$$b29
000282299 7001_ $$aBuck, Allyson$$b30
000282299 7001_ $$aHollberg, Bret$$b31
000282299 7001_ $$00009-0002-3231-4197$$aChapleau, Ron$$b32
000282299 7001_ $$00009-0009-4284-9129$$aDekker, Hanka$$b33
000282299 7001_ $$aCampbell, Susan G$$b34
000282299 7001_ $$aAbbink, Truus E M$$b35
000282299 7001_ $$aLeferink, Prisca S$$b36
000282299 7001_ $$00000-0001-8912-0954$$avan der Knaap, Marjo S$$b37
000282299 773__ $$0PERI:(DE-600)1491874-2$$a10.1212/WNL.0000000000214320$$gVol. 105, no. 11, p. e214320$$n11$$pe214320$$tNeurology$$v105$$x0028-3878$$y2025
000282299 8564_ $$uhttps://pub.dzne.de/record/282299/files/DZNE-2025-01269_SUPP1.pdf
000282299 8564_ $$uhttps://pub.dzne.de/record/282299/files/DZNE-2025-01269_SUPP2.pdf
000282299 8564_ $$uhttps://pub.dzne.de/record/282299/files/DZNE-2025-01269_SUPP3.pdf
000282299 8564_ $$uhttps://pub.dzne.de/record/282299/files/DZNE-2025-01269.pdf$$yRestricted
000282299 8564_ $$uhttps://pub.dzne.de/record/282299/files/DZNE-2025-01269_SUPP1.pdf?subformat=pdfa$$xpdfa
000282299 8564_ $$uhttps://pub.dzne.de/record/282299/files/DZNE-2025-01269_SUPP2.pdf?subformat=pdfa$$xpdfa
000282299 8564_ $$uhttps://pub.dzne.de/record/282299/files/DZNE-2025-01269_SUPP3.pdf?subformat=pdfa$$xpdfa
000282299 8564_ $$uhttps://pub.dzne.de/record/282299/files/DZNE-2025-01269.pdf?subformat=pdfa$$xpdfa$$yRestricted
000282299 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810795$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000282299 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282299 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2025-01-02$$wger
000282299 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROLOGY : 2022$$d2025-01-02
000282299 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000282299 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000282299 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000282299 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-02
000282299 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000282299 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-02
000282299 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-02
000282299 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-02
000282299 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000282299 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000282299 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROLOGY : 2022$$d2025-01-02
000282299 9201_ $$0I:(DE-2719)5000005$$kAG Schöls$$lClinical Neurogenetics$$x0
000282299 980__ $$ajournal
000282299 980__ $$aEDITORS
000282299 980__ $$aVDBINPRINT
000282299 980__ $$aI:(DE-2719)5000005
000282299 980__ $$aUNRESTRICTED